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Abstract Status epilepticus (SE) prognosis is related to
nonmodifiable factors (age, etiology), but the exact role of
drug treatment is unclear. This study was undertaken to
address the prognostic role of treatment adherence to
guidelines (TAG). We prospectively studied over
26 months a cohort of adults with incident SE (excluding
postanoxic). TAG was assessed in terms of drug doses
(±30 % of recommendations) and medication sequence; its
prognostic impact on mortality and return to baseline
conditions was adjusted for etiology, SE severity [Status
Epilepticus Severity Score (STESS)], and comorbidities.
Of 225 patients, 26 (12 %) died and 82 (36 %) were dis-
charged with a new handicap; TAG was observed in 142
(63 %). On univariate analysis, age, etiology, SE severity,
and comorbidities were significantly related to outcome,
while TAG was associated with neither outcome nor like-
lihood of SE control. Logistic regression for mortality
identified etiology [odds ratio (OR) 18.8, 95 % confidence
interval (CI) 4.3–82.8] and SE severity (STESS C3; OR
1.7, 95 % CI 1.2–2.4) as independent predictors, and for
lack of return to baseline, again etiology (OR 7.4, 95 % CI
3.9–14.0) and STESS C3 (OR 1.7, 95 % CI 1.4–2.2).
Similar results were found for the subgroup of 116 patients
with generalized-convulsive SE. Receiver operator char-
acteristic (ROC) analyses confirmed that TAG did not
improve outcome prediction. This study of a large SE
cohort suggests that treatment adherence to recommenda-
tions using current medications seems to play a negligible
prognostic role (class III), confirming the importance of the
biological background. Awaiting further treatment trials, it
appears mandatory to apply resources towards identifica-
tion of new therapeutic approaches.
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Introduction
Status epilepticus (SE) represents, after stroke, the most
common neurological emergency, with a significant risk of
mortality and morbidity [15, 21]. Several independent
studies identified some clinical prognostic predictors,
especially acute or potentially fatal etiology, advanced age,
de novo presentation, and severe consciousness impair-
ment before treatment [10, 14, 26, 35]. These nonmodifi-
able variables reflect the biological background and the
extent of brain damage, as opposed to drug treatment;
however, the specific prognostic role of SE treatment
quality has surprisingly received scarce attention to date.
Some studies reported worse outcome after SE if treatment
did not follow guidelines [3, 31, 37], but others did not
[20, 30].
Given the aforementioned divergent results, and in view
of the consistent large effort invested by several national
societies and international organizations in producing
treatment recommendations for SE, despite a disappointing
paucity of good evidence apart from for first-line therapy
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[9, 18, 29, 33, 34], it appears important to better estimate
the impact of SE treatment quality on patient prognosis.
Patients and methods
Patients
We analyzed our prospective registry that includes con-
secutive patients older than 16 years with incident SE
admitted to our center, enrolled during the period 1 April
2008 to 31 May 2011 (26 months). Further details on our
clinical cohort have been published elsewhere [22]. Briefly,
SE was defined as continuous occurrence of seizures during
more than 5 min, as suggested by the operational definition
[16], or repeated epileptic seizures without baseline
recovery in between. Seizures were diagnosed clinically,
but electroencephalography (EEG) confirmation was
required for nonconvulsive episodes. SE episodes were
identified by neurological consultants at the emergency and
intensive care units, and by EEG staff. Subjects with pos-
tanoxic SE were excluded. This study was approved by our
Ethic Commission.
Variables
Demographical and clinical data included age, gender,
history of previous seizures, worst seizure type (partial
versus generalized), level of consciousness before treat-
ment (alert or somnolent, versus stuporous or comatose),
and SE etiology; all were recorded prospectively. A vali-
dated SE clinical severity score [28] (STESS; including
age, previous seizures, seizure type, and consciousness)
was calculated upon admission according to the situation
before treatment start (0–6 points), and categorized as C3
(poor outcome prediction) versus \3 (good outcome pre-
diction). Etiology was considered as ‘‘potentially fatal’’ if
potentially leading per se to death if not specifically trea-
ted, as detailed in previous works [22, 26]; this classifica-
tion seems to account for SE prognosis better than the
International League Against Epilepsy (ILAE) classifica-
tion [1, 22, 26].
Detailed medication administration to treat SE was also
collected prospectively. This included drug type, adminis-
tration route, loading dosage per body weight, and
sequence of administration. The exact timing of adminis-
tration was available only for the first medication and was
dichotomized at 1 h following the beginning of the SE
episode. SE treatment was compared with the in-house
protocol in use since 2007, which is in agreement with the
2005 Swiss guidelines [13]. The recommendation includes
the following intravenous treatment administrations: as
first line, a slow bolus of lorazepam 0.1 mg/kg, clonaze-
pam 0.015 mg/kg, or midazolam 0.2 mg/kg; as second line,
phenytoin 20 mg/kg, or valproate 20 mg/kg, or leveti-
racetam 20 mg/kg; as third line, propofol 2 mg/kg fol-
lowed by 2–10 mg/kg/h, or midazolam 0.2 mg/kg followed
by 0.2–0.6 mg/kg/h, or thiopental 2 mg/kg followed by
2–5 mg/kg/h (anesthetics are titrated aiming at a burst-
suppression EEG with 10 s interburst interval). Treatment
was considered ‘‘adherent’’ if within a ±30 % range of
recommended dosage; the two following exceptions were
accepted: (a) more generous benzodiazepine loading doses
in patients with delirium tremens, (b) second-line admin-
istration of the usual antiepileptic drug (other than the
aforementioned compounds) if suspected to be withdrawn
in patients with epilepsy. Treatment was considered
‘‘nonadherent’’ if the dosage of any drug was (a) lower
(undertreatment) or (b) greater (overtreatment) than the
30 % range, or (c) was wrong, i.e., the treatment sequence
was not respected (e.g., phenytoin as first line; anesthetic
agent given together with the second-line drug in patients
with simple-partial, complex-partial, or myoclonic SE
without respiratory or cardiovascular impairment).
The Charlson Comorbidity Index (CCI), a validated
composite score of 19 different medical conditions, was
used to quantify active medical conditions preceding SE
(apart from its etiology), weighted by the risk of 1-year
mortality [4]. CCI was calculated after hospital discharge,
from the computerized medical files, and categorized into
three groups: CCI = 0, CCI = 1–2, and CCI = 3–19.
Outcome at hospital discharge represented the primary
outcome; it was prospectively categorized into three,
mutually exclusive items: return to baseline (premorbid
functional and neurological) status, new disability, or
death.
Statistical analyses
Each potential predictor of the SE outcomes ‘‘lack of return
to baseline’’ (i.e., mortality or new disability) and ‘‘mor-
tality’’ was analyzed individually for its relationship with
each outcome, using v2 or two-sided Fisher exact tests
when appropriate. Stepwise logistic regressions were per-
formed to analyze the role of potential predictors, using
etiology, SE severity (STESS score, which includes age),
medical comorbitity, and treatment adherence. Goodness
of fit was assessed using v2 tests. We calculated receiver
operator characteristic (ROC) curves for the different
models, using a nonparametric approach and applying
Bonferroni corrections to obtain a global P \ 0.05 in case
of multiple comparisons; for this analysis, every medical
condition included in the CCI was also considered as an
individual variable. Calculations were performed using
Stata software (version 9; College Station, TX).
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Results
Among 263 SE episodes recorded during the study period,
we identified 225 (86 %) incident patients. Mean patient
age was 61.1 (±18.4) years, and 102 (45 %) were women;
93 (41 %) had a known epilepsy diagnosis, and 97 (43 %)
experienced a potentially fatal etiology. SE lasted between
5 and 29 min before diagnosis in 27 (12 %) subjects.
Regarding semiology, 32 (14 %) experienced simple-par-
tial, 71 (32 %) complex-partial, 106 (47 %) generalized-
convulsive, 10 (4 %) subtle, 5 (2 %) absence, and 1
myoclonic (genetic generalized epilepsy) SE forms; 134
(56 %) had a severe consciousness impairment before
treatment, defined as stupor (arousal without response) or
coma. Treatment was delayed for more than 1 h after the
beginning of SE in 139 (62 %) patients. In this subgroup,
the prevalence of generalized-convulsive SE was clearly
lower than in patients treated within 1 h (54/139 versus
62/86, P \ 0.001, v2). Treatment was judged not adherent
to guidelines in 83 (37 %) patients, while in 6 patients
treatment adherence could not be assessed [1 patient died
before treatment institution, while in another 5 (who
returned to baseline) the SE episode stopped spontane-
ously]; for further analyses, these subjects were added to
the ‘‘adherent’’ group.
Regarding outcome, 26 (12 %) patients died and 82
(36 %) left our hospital with a new disability. Demo-
graphics and relevant clinical variables of the studied
cohort, stratified according to functional outcome at hos-
pital discharge, are illustrated in Table 1. While age, eti-
ology, SE severity (STESS score), and comorbidity were
significantly related to outcome, treatment latency and
adherence were not. Considering the subgroup of 116
patients with generalized-convulsive and nonconvulsive SE
in coma, representing the most severe forms of SE, lack of
treatment adherence to guidelines was again not related to
mortality (5/12 patients with fatal outcome were treated
violating guidelines versus 31/104 surviving, P = 0.51,
Fisher) or return to baseline conditions (19/50 not returning
to baseline received treatment not adherent to guidelines
versus 17/66 returning to baseline, P = 0.16, v2). Table 2
details the reasons for nonadherent treatment according to
outcome: no statistical difference emerged, even if the
proportion of nonadherent treatment was lowest in patients
with the most favorable outcome (i.e., return to baseline).
Table 3 shows treatment adherence according to several
clinical and demographical variables. Greater latency to
treatment institution was related to any violation in the
treatment protocol, and patients with a potentially fatal
etiology tended to be treated more often with high dosages.
Even if nonsignificant, higher age tended somewhat to be
related to medication underdosage (especially benzodi-
azepines, data not shown), while patients with greater
severity (STESS) were somewhat more likely to receive
high drug dosages. Finally, in 13 patients (6 % of the total,
all with fatal outcome) the SE episode was not controlled;
the distribution of noncontrolled episodes among adherent
and nonadherent treatment groups resulted similar.
Logistic regression modeling using mortality as the
dependent variable identified potentially fatal etiology (OR
18.8, 95 % CI 4.3–82.8) and STESS C3 (OR 1.7, 95 % CI
1.2–2.4) as independent predictors, while treatment
adherence (dichotomous) and CCI were not. As regards
lack of return to baseline clinical conditions, results were
similar: potentially fatal etiology (OR 7.4, 95 % CI
3.9–14.0) and STESS C3 (OR 1.7, 95 % CI 1.4–2.2) were
independently related to this outcome, as opposed to
treatment adherence and CCI. All models showed accept-
able goodness of fit, apart from those including CCI for
return to baseline. To further analyze the role of treatment
quality, we constructed ROC curves for the two outcomes
(mortality, lack of return to baseline) using four models.
The results are given in Figs. 1 and 2. While for both
outcomes the prognostic accuracy (area under the curve)
significantly improved after adding STESS to etiology
(and, for baseline return, also adding CCI), consideration of
treatment adherence did not show any notable impact on
prediction. For these comparisons, significance was set at
P \ 0.017 (Bonferroni).
Discussion
This study provides class III evidence that SE drug treat-
ment, after consideration of robust predictors such as eti-
ology, SE severity including age, and comorbidities, seems
to have no major effect on prognosis even if administered
violating current guidelines.
Two decades ago, a multicenter retrospective assess-
ment on 346 patients with convulsive SE in The Nether-
lands showed that ‘‘insufficient’’ treatment was more
frequent in patients who died (45 %) or had new sequelae
(22 %), as compared with those having good outcome
(10 %) [31]. A prospective comparison of 57 adults with
SE between a rural and an urban center in Italy disclosed
better prognosis in the former [37]; the authors showed that
better medical management in the peripheral hospital (83
versus 73 % of ‘‘appropriate’’ treatment) was strongly and
independently related to clinical outcome (OR 21.09). A
subsequent prospective study by our group comparing
treatment appropriateness in 54 adult patients between our
tertiary referral center and peripheral hospitals in our
region did not support that hypothesis, since the functional
prognosis of subjects treated in the referral center was not
different, despite significantly better application of SE
treatment guidelines (97 % in the center, 78 % in
J Neurol (2013) 260:421–428 423
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peripheral settings) [30]. This is in line with a retrospective
Canadian analysis on 45 adults with convulsive SE: while
71 % of them received appropriate treatment, their clinical
outcome was similar, apart from SE length [20]. Most
recently, another prospective study carried out in France,
including 101 adults with generalized-convulsive SE,
identified treatment adherence to guidelines as a powerful
and independent predictor of seizure control: initial treat-
ment according to local recommendations had a 74 %
efficacy rate versus 29 % in cases with protocol violations
Table 1 Demographics and
clinical data of incident patients
with SE according to outcome
SE status epilepticus, CCI
Charlson Comorbidity Index,
STESS Status Epilepticus
Severity Score
Mortality
(%)
New disability
(%)
Return to baseline
(%)
P value Test
Total 26/225
(11.6)
82/225 (36.4) 117/225 (52.0)
Age C65 years 17/26
(65.4)
53/82 (64.6) 34/117 (29.0) \0.001 v2
Potentially fatal etiology 24/26
(92.3)
48/82 (58.5) 25/117 (21.4) \0.001 v2
Treatment latency [1 h 15/26
(57.7)
53/82 (64.6) 71/117 (60.4) 0.769 v2
STESS C3 21/26
(80.8)
58/82 (70.7) 51/117 (43.6) \0.001 v2
CCI
0 3/26 (11.6) 24/82 (29.3) 45/117 (38.5) \0.001 Fisher
1–2 3/26 (11.6) 28/82 (34.1) 39/117 (33.3)
3 20/26
(76.9)
30/82 (36.6) 33/117 (28.2)
Treatment not adherent to
guidelines
13/26
(50.0)
33/82 (40.2) 37/117 (32) 0.157 v2
Table 2 Comparison of
reasons for SE treatment not
adherent to guidelines according
to SE outcome
SE status epilepticus
Treatment Mortality (%) New disability (%) Return to baseline (%) P value Test
Overdosed 2/26 (7.7) 3/82 (3.7) 4/117 (3.4) 0.542 Fisher
Underdosed 7/26 (26.9) 20/82 (24.4) 23/117 (19.7) 0.579 Fisher
Wrong sequence 6/26 (23.1) 17/82 (20.7) 14/117 (12) 0.153 Fisher
Table 3 Comparison of drug
SE treatment appropriateness
stratified by demographics and
clinical factors
SE status epilepticus, CCI
Charlson Comorbidity Index,
STESS Status Epilepticus
Severity Score
a Of the remaining patients, six
could not be assessed as regards
their treatment adherence to
guidelines; 83 were treated
violating the guidelines
Treatment adherent
to guidelinesa (%)
Overdosed
treatment
(%)
Underdosed
treatment (%)
Wrong
treatment
sequence (%)
P value Test
Total 136/225 (60.4) 9/225 (4.0) 50/225 (22.2) 37/225 (16.4)
Age
C65 years
56/136 (41.2) 4/9 (44.4) 31/50 (62.0) 21/37 (56.8) 0.279 Fisher
Potentially
fatal
etiology
53/136 (39.0) 7/9 (77.7) 23/50 (46.0) 19/37 (51.4) 0.091 Fisher
Treatment
latency
[1 h
69/136 (50.7) 7/9 (77.7) 39/50 (78.0) 32/37 (85.6) \0.001 Fisher
STESS C3 79/136 (56.8) 8/9 (88.8) 31/50 (62.0) 20/37 (54.1) 0.273 Fisher
CCI
0 44/136 (32.4) 1/9 (11.1) 15/50 (30.0) 12/37 (32.4) 0.431 Fisher
1–2 39/136 (28.6) 3/9 (33.3) 15/50 (30.0) 16/37 (43.2)
3 53/136 (39.0) 5/9 (55.5) 20/50 (40.0) 9/37 (24.3)
SE not
controlled
7/136 (5) 1/9 (11) 3/50 (6) 4/37 (11) 0.417 Fisher
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[3]. The various results of these studies probably reflect
different SE definitions, patient selections, etiologies,
treatment protocols, definitions of treatment appropriate-
ness, and the chosen outcome; For instance, the French
study [3] was limited to convulsive SE and its protocol was
rather peculiar as compared with the French guidelines
[23]; furthermore, participating physicians received spe-
cific training before the study, criteria regarding treatment
appropriateness were not detailed, and data on clinical
outcome were not described. Most importantly, in all
mentioned studies the impact of treatment was not adjusted
for other known SE outcome predictors.
Our prospective analysis, which includes more patients
than the three previous prospective studies taken together
[3, 30, 37] and is not limited to generalized-convulsive SE,
suggests that adherence of specific SE drug treatment to
recommendations plays a relatively negligible prognostic
role. This underscores the robustness of other predictors,
independently identified by several groups over the last two
decades. Increasing age and acute (or potentially fatal)
etiology seem the most important variables [10, 14, 26,
35]; the extent of consciousness impairment and seizure
type also play an independent role in some studies [26, 32],
while the delay to treatment start has yielded divergent
results, possibly owing to its relationship with seizure type
(complex-partial or absence SE may last for a relatively
long time without major sequelae), or the loss of predictive
performance after the first few hours [7, 14, 26, 35].
Concomitant medical conditions may also be related to
prognosis [2, 12]. We therefore designed our analysis to be
lavretniecnedifnoc%59aerA
Model 1 
87.0ygoloitelatafyllaitnetoP 0.71 - 0.84 
Model 2 
48.0SSETS,ygoloitelatafyllaitnetoP 0.78  - 0.91 
Model 3 
19.0ICC,SSETS,ygoloitelatafyllaitnetoP 0.86 - 0.96 
Model 4 
Potentially fatal etiology, STESS, CCI, treatment appropriateness 0.91 0.87 – 0.97 
P= 0.002 
CCI: Charlson comorbidity index; STESS= status epilepticus severity score. 
Model 1 vs. Model 2 P=0.121 
Model 2 vs. Model 3 P=0.005 
Model 3 vs. Model 4 P=0.259 
Fig. 1 Assessment of different
models for the prediction of
mortality in 225 patients with
incident status epilepticus
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adjusted for the most important predictors: etiology, the
validated STESS score, and comorbitities.
We did not find a significant prognostic role of SE drug
treatment quality on outcome; this may reflect the fact that
antiepileptic compounds administered in this clinical set-
ting are exclusively ‘‘symptomatic,’’ and that an etiological
SE treatment proves often difficult (either the etiology is
not know or it is not responsive to treatments, e.g., in some
autoimmune forms or in devastating brain injuries). We
cannot formally exclude that an effect of treatment quality
might be observed in a much larger cohort; however, our
results indicate that this role would be rather marginal.
Nevertheless, based on our analyses, we believe that fur-
ther studies of the role of a wrong medication sequence on
prognosis, which seems to bear a somewhat greater risk of
poor outcome as compared with over- or underdosage,
should be conducted. We observed that treatment latency
[1 h was significantly related to underdosage and incor-
rect drug sequence. This association possibly illustrates
that, in presence of SE forms other than generalized con-
vulsions, longer treatment delay and reduced adherence to
guidelines may coexist because of a perceived lower risk of
sequelae. Conversely, with potentially fatal SE etiologies
and higher STESS score, slightly more patients received
overdosed drugs, possibly reflecting a propensity for more
aggressive treatments in severe cases.
This observational study reflects practice in our center:
at the beginning, patients are mostly treated by paramedics,
emergency physicians, and/or consultant neurologists.
Epileptologists are involved only after SE is suspected (and
during working days). Protocol ‘‘violations’’ occurred
despite the fact that every consultant neurologist and
lavretniecnedifnoc%59aerA
Model 11 
27.0ygoloitelatafyllaitnetoP 0.66 - 0.77 
Model 12 
08.0SSETS,ygoloitelatafyllaitnetoP 0.74  - 0.86 
Model 13 
58.0ICC,SSETS,ygoloitelatafyllaitnetoP 0.79 - 0.90 
Model 14 
Potentially fatal etiology, STESS, CCI, treatment appropriateness 0.85 0.80 – 0.90 
P< 0.001 
CCI: Charlson comorbidity index; STESS= status epilepticus severity score. 
Model 11 vs. Model 12 P<0.001 
Model 12 vs. Model 13 P=0.011 
Model 13 vs. Model 14 P=0.749 
Fig. 2 Assessment of different
models for the prediction of lack
of return to baseline clinical
conditions in 225 patients with
incident status epilepticus
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emergency physician is periodically informed on the
treatment flow for patients with SE, and might in part also
reflect particular clinical situations (such as the use of low
benzodiazepine doses in elderly subjects). We believe that
this is similar to most centers.
This study has some limitations. First, it is based on
Swiss SE treatment guidelines [13]; however, apart from
clonazepam, which is popular in French-speaking countries
[23], this treatment protocol is extremely similar to other
current national and international guidelines [9, 18, 19, 33,
36]. Second, the definition of appropriateness implies some
arbitrary judgment; we chose a deviation of 30 % in the
dosage, or an alteration of the medication sequence, as we
believe that these ‘‘violations’’ may prove of clinical
importance (e.g., the load of 1 g phenytoin in a 75-kg
patient is mostly felt to be insufficient). While we
acknowledge that this approach was not based on previous
evidence, it allows uniform scoring of treatment appro-
priateness throughout the cohort. In this context, we
emphasize that previous studies provided far less clear
criteria about treatment quality [3, 20, 30, 37]. Third, our
study is a clinical cohort observed in one academic setting
only. However, it is characterized by a prospective design
with homogeneous assessment criteria over the entire
recruitment period, elements that in our view corroborate
its internal validity. We also believe that the external
validity of our results is warranted for similar hospitalized
patients in comparable settings, as demographics and
mortality are in line with most population-based studies in
Europe [5, 8, 11], and, to a broader extent, North America
[6, 14, 38] (especially after exclusion of postanoxic
encephalopathy [27]). Fourth, although large as compared
with previous studies, our number of cases might prevent
identification of small effects of treatment on prognosis; to
identify a difference of 5 % in return to baseline conditions
(e.g., 55 versus 50 %), a sample of more than 3,000
patients would be required (power 0.8, alpha error 0.05).
This would imply that at least 10 centers would recruit for
over 2 years. Finally, no patient in this cohort was treated
with extreme protocol violations (e.g., huge toxic doses or
pseudoplacebos of any medication, as almost all violations
were included in a window of 33–200 % of the recom-
mended doses); it nevertheless is likely that in such a set-
ting the clinical outcome would be markedly influenced by
‘‘treatment’’.
Our findings, although somewhat surprising, may have
an important practical impact on clinical practice. They
corroborate the role of nonmodifiable clinical predictors,
representing the biological background on which the SE
occurs: the fact that patients with noncontrolled SE were
similarly distributed among adherent and nonadherent
treatment groups further suggests that, if SE is per se
‘‘treatable’’ according to its underlying background, it may
be controlled with further treatment despite inadequate
initial management. Pending well-designed drug trials in
patients with SE, the present results may challenge the
need of further detailed SE treatment guidelines. Protocols
are certainly useful in smoothing and fastening the interplay
of medical personnel involved in management of SE [9, 24,
29, 33], and we continue to use a protocol in our institution,
but it seems that identification of new specific therapeutic
approaches targeting, for example, the etiology, epilepto-
genic mechanisms, or inflammation [17, 25], is urgently
needed, since the role of medical treatment appears marginal
using the current antiepileptic drug arsenal.
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